CAD Therapeutics, Inc. — SEC Form D Filing
CAD Therapeutics, Inc. filed an SEC Form D on October 2, 2026, reporting $4.00M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 2, 2026
- Amount reported
- $4.00M
- Round stage
- Series A because the company raised $4,000,000 through the issuance of Series A common stock to fund its early-stage clinical development.
- Industry
- Biotechnology
- Website
- https://cadtherapeutics.com
What the company does
Securities: Equity, SERIES A COMMON STOCK. Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Patients suffering from critical-care cardiovascular conditions and heparin-induced thrombocytopenia lack safe and effective targeted anticoagulation therapies.
Solution
CAD Therapeutics develops novel cardiovascular therapies, including CAD-1005 and tecarfarin, to address acute kidney injury and provide chronic anticoagulation.
Why now
The rising global prevalence of cardiovascular diseases combined with recent regulatory pathways for orphan drug designations has created an urgent demand for specialized cardiovascular therapies.
Source: SEC EDGAR Form D filing